Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- Toray Industries
- Pfizer
- National Institutes of Health
- GlaxoSmithKline
- Gilead Sciences
- UCB
- Boehringer Ingelheim
- MedImmune
This publication has 142 references indexed in Scilit:
- Interferon-inducible chemokines reflect severity and progression in sarcoidosisRespiratory Research, 2013
- Molecular and cellular mechanisms of pulmonary fibrosisFibrogenesis & Tissue Repair, 2012
- Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damageAnnals of the Rheumatic Diseases, 2012
- Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- What are biomarkers?Current Opinion in HIV and AIDS, 2010
- Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patientsArthritis Research & Therapy, 2009
- Gene Expression Profiling Identifies MMP-12 and ADAMDEC1 as Potential Pathogenic Mediators of Pulmonary SarcoidosisAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Oxidative Stress, Plasminogen Activator Inhibitor 1, and Lung FibrosisAntioxidants & Redox Signaling, 2008
- Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosisJournal of the American Academy of Dermatology, 1995